A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AGN-241751 After Oral Administration in Healthy Volunteers
Latest Information Update: 04 Aug 2021
Price :
$35 *
At a glance
- Drugs Zelquistinel (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- 04 Aug 2021 New trial record